Eric J. Topol

TL;DR: In patients with high OTR, clopidogrel 150 mg/day results in a significant reduction in platelet reactivity, and the observed lack of effect in patients with 2 copies of a CYP2C19 LoF allele must be confirmed by larger studies.

TL;DR: This paper will review the substantive progress in the field, including recognition of major pitfalls, and lay the groundwork for future improvements in pharmacologic myocardial reperfusion treatment, with a focus on the GUSTO 1 trial.

TL;DR: Since acute myocardial infarction as an entity became the object of systematic study over 30 years ago, published reports on patients admitted to the hospital with (or who later developed) concomitant bundle branch block have emphasized their unfavorable short and long-term prognoses.

TL;DR: The Ser- 700 variant thrombospondin-1 was conformationally more labile than the Asn-700 variant as demonstrated by increased susceptibility to proteolytic digestion and enhanced susceptibility to unfolding by denaturants, suggesting a potential molecular and cellular basis for a genetic risk factor associated with early onset myocardial infarction.

TL;DR: Using low-molecular-weight heparin in conjunction with a GP IIb/IIIa inhibitor was safe and associated with a lower revascularization rate in the PARAGON B trial, and this findings support the rationale and promise for combining GP IIB/ IIIa blockers and LMWH for future management of acute coronary syndrome.